ONE Bio Appoints Mr. Feng Yu As New GM for Its Chemical and Herbal Extract Division

MIAMI, FL--(Marketwire - May 26, 2010) -

ONE Bio, Corp. (“ONE” or the “Company”) (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced that it has appointed Mr. Feng Yu, a senior sales executive and expert pharmacist, to the position of General Manager for its chemical and herbal extract division (“CHE”).

Feng Yu, age 32, residing in Sanming Fujian China, has held several senior positions in the pharmaceutical and nutraceutical fields including Deputy General Manager for Guangdong Oriental Son Pharmacy Co., Ltd. where he was responsible for R&D, production management and sales operation for the medicine and health products, CEO for Guangdong Qingyuan Shengzhitang Modern Traditional Chinese Medicine Co., Ltd., where he was in charge of the company’s operations and Project Manager and Secretary for League Committee in Pharma Innovation Center of Guangdong Qingyuan Medicine Group where he was responsible for new product development and submissions.

With his extensive experience in operations and sales Mr. Yu successfully led his team twice in passing the National GMP Authentication and took part in the development and implementation of several national and provincial science and technology projects in China. Mr. Yu graduated from the Department of Biological Pharmacy of China Pharmaceutical University in 2000 and acquired a Qualification Certificate as a National Licensed Pharmacist in 2002.

“We are very pleased to have Mr. Yu join us. Mr. Yu’s extensive experience in R&D for health products, quality control processes and marketing will serve us well as we continue to expand our product portfolio. Since his arrival we have already seen great strategies, initiatives and results from his execution and leadership,” stated Min Zhao, ONE Bio President (China).

“Mr. Yu’s addition to our team strengthens our management group in Asia,” stated ONE’s CEO, Mr. Marius Silvasan. “Mr. Yu’s strong operational experience combined to his know-how in the pharmaceutical and nutraceutical fields are key components towards ensuring that as we continue to experience organic growth adequate controls are implemented and enforced to maintain our operational efficiency,” added Silvasan.

About ONE Bio, Corp.
ONE Bio, Corp. (“ONE”) (OTCBB: ONBI) (www.onehcorp.com) headquartered in Miami, FL, is an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on capitalizing on the rapidly growing markets of the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE’s growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. Through ONE, small private companies gain access to capital, experienced management and strategic insight. ONE builds strong synergies amongst all subsidiaries to enhance shareholder value. ONE is working with each subsidiary to promote organic and acquisition driven growth.

This press release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” or “anticipates,” and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company’s expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company’s stock price. These risks and other factors are detailed in the Company’s regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company’s control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.